Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 6901–6950 of 75459
On April 4, 2025, the Board elected each of Joseph Onorati, Marco Santori and Zachary Tai as directors of the Company, to fill the vacancies on the Board.
- Parker White was appointed by the Board as the chief operating officer and chief investment officer of the Company.
Effective as of April 4, 2025, Samuel Haskell, Marcelo Lemos and Ned Siegel resigned from the Board and, to the extent applicable, all committees thereof.
The Board of Directors of ImmuCell Corporation (the Company) has elected Timothy C. Fiori, age 46, to serve as its Chief Financial Officer effective April 7, 2025.
On April 1, 2025, the board of directors (the “Board”) of Rain Enhancement Technologies Holdco, Inc. (the “Company”), increased the size of the Board from five to seven directors and appointed Mr. Marcus Peperzak and Mr. Robert Reardon to the Board to fill the resulting vacancies.
On April 1, 2025, the board of directors (the “Board”) of Rain Enhancement Technologies Holdco, Inc. (the “Company”), increased the size of the Board from five to seven directors and appointed Mr. Marcus Peperzak and Mr. Robert Reardon to the Board to fill the resulting vacancies.
appointed Matthew Stark as the Company’s Chief Financial Officer and a member of the Board of Directors.
accepted the resignation from Andrew Kucharchuk as the Company’s Chief Financial Officer and member of the Board of Directors.
the Board appointed Andrew E. Holm and Paula Schaefer to serve as directors, with Ms. Schaefer serving as an independent director, effective as of April 3, 2025.
the Board appointed Andrew E. Holm and Paula Schaefer to serve as directors, with Ms. Schaefer serving as an independent director, effective as of April 3, 2025.
On April 3, 2025, Rajat Dhanda and Daniel J. Sullivan, each a member of the board of directors (the “Board”) of the Company, notified the Company of their decisions to step down from their positions on the Board, which resignations became effective on that day.
On April 3, 2025, Rajat Dhanda and Daniel J. Sullivan, each a member of the board of directors (the “Board”) of the Company, notified the Company of their decisions to step down from their positions on the Board, which resignations became effective on that day.
On April 1, 2025, the Board of Directors of Healthcare Realty Trust Incorporated (the “Company”) appointed Peter A. Scott as the Company’s President and Chief Executive Officer, effective April 15, 2025.
Upon Mr. Park becoming the Chief Financial Officer, Gloria Nelund's tenure as the Company’s interim Chief Financial Officer ended and she continues in her longstanding positions as Chairman, President, and Chief Executive Officer of the Company.
On March 28, 2025, the board of managers (the “Board”) of TriLinc Global Impact Fund, LLC (the “Company”) appointed Kun Yong (Brent) Park, age 43, to serve as the Chief Financial Officer of the Company, effective as of April 1, 2025.
On April 1, 2025, the Board of Directors (the “ Board ”) of Braemar Hotels & Resorts Inc. (the “ Company ”) appointed Ms. Kellie Sirna to the Board, effective immediately, to serve until the next annual meeting of stockholders of the Company and until her successor is duly elected and qualified.
On the Closing Date, April 1, 2025, Mr. Takehiro Abe resigned from his positions as the Company’s Chief Executive Officer, Chief Financial Officer, President, Secretary, and Treasurer.
On the Closing Date, Mr. Ryohei Uetaki was appointed as the Company’s Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer, and Director.
Additionally, Mr. Abe resigned from his role as Director, with his resignation becoming effective on the 10th day after the mailing of the Company’s information statement on Schedule 14F-1 to the Company’s stockholders.
On April 2, 2025, Rajat Dhanda, a member of the board of directors (the “Board”) of Ares Industrial Real Estate Income Trust Inc. (referred to herein as the “Company,” “we,” “our,” or “us”), notified the Company of his decision to step down from his position on the Board, which became effective on that day.
On April 1, 2025, Scott Recknor, the Company’s Head of Asset Management, notified the Company of his decision to retire.
the Board appointed Martin A. Edmondson to serve as a director on the Board.
Effective April 4, 2025, Eeva Hakoranta will no longer be serving as Chief Licensing Officer.
On April 2, 2025, Robert C. Griffin, a director of the Company since July 2005, and current Chairman of the Board of the Company, informed the Company that he will be retiring from the Board of the Company, without standing for re-election at the 2025 Annual Meeting of Stockholders.
On March 31, 2025, the majority voting stockholder of General Enterprise Ventures, Inc. (the “Corporation”) approved the appointment of the following persons as members of the Board of Directors (the “Board”) of the Corporation, effective April 1, 2025: Theodore Ralston Jeffrey Pomerantz John Costa
On March 31, 2025, the Board of the Corporation approved the appointment of the following persons as officers (each, an “Officer” and collectively, the “Officers”) of the Corporation, effective April 1, 2025: Theodore Ralston President and Chief Executive Officer Nanuk Warman Secretary and Chief Financial Officer Joshua Ralston Vice President of Operations Anthony Newton General Counsel
On March 31, 2025, the Board of the Corporation approved the appointment of the following persons as officers (each, an “Officer” and collectively, the “Officers”) of the Corporation, effective April 1, 2025: Theodore Ralston President and Chief Executive Officer Nanuk Warman Secretary and Chief Financial Officer Joshua Ralston Vice President of Operations Anthony Newton General Counsel
On March 31, 2025, the Board of the Corporation approved the appointment of the following persons as officers (each, an “Officer” and collectively, the “Officers”) of the Corporation, effective April 1, 2025: Theodore Ralston President and Chief Executive Officer Nanuk Warman Secretary and Chief Financial Officer Joshua Ralston Vice President of Operations Anthony Newton General Counsel
On March 31, 2025, the majority voting stockholder of General Enterprise Ventures, Inc. (the “Corporation”) approved the appointment of the following persons as members of the Board of Directors (the “Board”) of the Corporation, effective April 1, 2025: Theodore Ralston Jeffrey Pomerantz John Costa
On March 31, 2025, the Board of the Corporation approved the appointment of the following persons as officers (each, an “Officer” and collectively, the “Officers”) of the Corporation, effective April 1, 2025: Theodore Ralston President and Chief Executive Officer Nanuk Warman Secretary and Chief Financial Officer Joshua Ralston Vice President of Operations Anthony Newton General Counsel
On March 31, 2025, the majority voting stockholder of General Enterprise Ventures, Inc. (the “Corporation”) approved the appointment of the following persons as members of the Board of Directors (the “Board”) of the Corporation, effective April 1, 2025: Theodore Ralston Jeffrey Pomerantz John Costa
On April 4, 2025, Kenneth M. Greenwood, Chief Product Architect, notified Healthcare Integrated Technologies, Inc. (the “Company”) of his resignation from all positions with the Company, effective immediately.
On March 31, 2025, Michael R. Edwards notified Caleres, Inc. (the “Company”) of his decision to resign as the Company’s Division President – Famous Footwear, effective May 2, 2025.
On April 1, 2025 , the Board of Directors (the “Board”) of Nordstrom, Inc. appointed the Corporation’s Vice President – Controller, Randy Kanai, age 50, to the position of Interim Chief Accounting Officer.
Retirement of Gerald Ng: Gerald Ng, Vice President and Chief Financial Officer of Data I/O Corporation (the “Company”), announced his planned retirement and upcoming transition, which is expected to take place in the second quarter of 2025.
appointed Kevin D. Chapman, Renasant’s President and Chief Operating Officer and a member of the Bank Board, to fill this new seat on the Board
Kevin D. Chapman assuming the role of the Company’s and the Bank’s Chief Executive Officer on the Transition Date (as previously disclosed)
appointed each of M. Ray (Hoppy) Cole, Jr., Jonathan A. Levy, Renee Moore, and Ted E. Parker to fill the new seats on the Board, effective as of the Effective Time
appointed each of M. Ray (Hoppy) Cole, Jr., Jonathan A. Levy, Renee Moore, and Ted E. Parker to fill the new seats on the Board, effective as of the Effective Time
appointed each of M. Ray (Hoppy) Cole, Jr., Jonathan A. Levy, Renee Moore, and Ted E. Parker to fill the new seats on the Board, effective as of the Effective Time
appointed each of M. Ray (Hoppy) Cole, Jr., Jonathan A. Levy, Renee Moore, and Ted E. Parker to fill the new seats on the Board, effective as of the Effective Time
E. Robinson McGraw, the Company’s Executive Chairman and the Chairman of the Board and of the Bank Board, agreed with the Company that he would resign as an officer and employee of the Company and the Bank, effective May 1, 2025 (the “Transition Date”)
Dr. Keswani will succeed Dr. Roberts, who has served as Chief Medical Officer for the past seven years, and who agreed to remain with the Company in a strategic advisory role following her succession by Dr. Keswani.
On April 2, 2025, Sanjay Keswani, M.D. agreed to succeed Eiry W. Roberts, M.D. as the Chief Medical Officer of Neurocrine Biosciences, Inc. (“Neurocrine Biosciences” or the “Company”), effective June 2, 2025.
On April 1, 2025, the Company appointed Scott Garula, currently President of Cintas’ Rental Division, to succeed Mr. Hansen as Executive Vice President & CFO, effective June 1, 2025.
J. Michael Hansen notified Cintas Corporation (the “Company”) of his intent to retire from his role as Executive Vice President & Chief Financial Officer (“CFO”).
on March 18, 2025, the Board approved, effective on April 1, 2025, (i) the removal of Thomas Krywe as interim Chief Financial Officer, principal financial officer and principal accounting officer of the Company and (ii) the appointment of Alison Engel as Chief Financial Officer, principal financial officer and principal accounting officer of the Company.
on March 18, 2025, the Board approved, effective on April 1, 2025, (i) the removal of Thomas Krywe as interim Chief Financial Officer, principal financial officer and principal accounting officer of the Company and (ii) the appointment of Alison Engel as Chief Financial Officer, principal financial officer and principal accounting officer of the Company.
Kathy Vrabeck retired from the Company as its Chief Operating Officer, effective as of April 1, 2025.
On April 3, 2025, Paul L. Berns informed the Board of Directors (the “Board”) of UNITY Biotechnology, Inc. (“Unity” or the “Company”) of his resignation as a member of the Board of the Company, and all of the committees of the Board on which he serves, in each case, effective at the close of business on April 4, 2025.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.